SCHEMBL2904413

SCHEMBL2904413

CC(C)(COS(C)(=O)=O)CN1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.43
ATM Q13315 2/20 0.42
TDP1 Q9NUW8 2/20 0.41
CYP2D6 P10635 1/20 0.32
MAPK1 P28482 1/20 0.32
CHRM2 P08172 2/20 0.32
CHRM4 P08173 2/20 0.32
CHRM5 P08912 2/20 0.32
CHRM1 P11229 2/20 0.32
CHRM3 P20309 2/20 0.32
LMNA P02545 2/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
USP2 O75604 1/20 0.31
MMP9 P14780 1/20 0.31
ALOX15 P16050 1/20 0.31
GAA P10253 1/20 0.31
GLA P06280 1/20 0.31
MAPT P10636 1/20 0.31
RECQL P46063 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16993333 0.77 USP2 (0.42) CHRM2CHRM4CHRM1CHRM3USP2
SCHEMBL9130270 0.75 USP2 (0.46) TSHRLMNAALDH1A1KDM4EUSP2
SCHEMBL797426 0.74 ALDH1A1 (0.37) TSHRCYP2D6MAPK1CHRM2CHRM4
SCHEMBL11501574 0.72 LMNA (0.36) TSHRATMTDP1CHRM5LMNA
SCHEMBL6957204 0.71 ALDH1A1 (0.39) TSHRCYP2D6MAPK1CHRM2CHRM4
SCHEMBL5857647 0.71 TSHR (0.36) TSHRATMTDP1ALDH1A1KDM4E
SCHEMBL2075399 0.71 KDM4E (0.44) TSHRCYP2D6MAPK1LMNAALDH1A1
SCHEMBL2077149 0.71 KDM4E (0.44) TSHRCYP2D6MAPK1LMNAALDH1A1
SCHEMBL12718302 0.69 ALDH1A1 (0.37) TSHRLMNAALDH1A1HRH3
SCHEMBL10656 0.69 USP2 (0.40) TSHRLMNAALDH1A1KDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010506-B1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS HOFFMANN LA ROCHE (CH) 2010-08-04 EP disclosed
US-7632829-B2 Diazepan derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-15 US disclosed
EP-2010506-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-Roche AG (CH) 2009-01-07 EP disclosed
WO-2007122103-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-01 WO disclosed
US-20070249589-A1 Novel diazepan derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249589-A1 Novel diazepan derivatives CCR3, CCR1, CCR10 TSHR 571/4885ATM 2054/4885TDP1 3846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.